Parkinson's UK launches GBP1m virtual biotech company to create new treatments.
M2 PHARMA-March 9, 2017-Parkinson's UK launches GBP1m virtual biotech company to create new treatments
(C)2017 M2 COMMUNICATIONS
Parkinson's UK has teamed up with the University of Sheffield to launch a GBP1m virtual biotech company to create new treatments for the disease, the charity announced on Wednesday.
The move is thought to be the first time that a charity has approached a research partner to set up an offshoot company in this way.
The new company, Keapstone Therapeutics, will combine the university's world-leading research with funding and expertise from the charity. This will be channelled to develop new treatments for Parkinson's.
Researchers at the University of Sheffield have already identified small 'drug-like' molecules that can activate a possible in-built defence system to help protect brain cells from oxidative stress - which causes damage to brain tissue and cells, and plays a key role in the disease.
Keapstone Therapeutics will further develop these molecules, which it is hoped could become new drugs to slow or halt the progression of Parkinson's.
Commenting on the partnership, Parkinson's UK's director of research, Arthur Roach, said that the creation of a spinout biotech company would allow it to investigate and develop potential treatments "with an intensity that is unprecedented for a charity".
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 9, 2017|
|Previous Article:||TiGenix announces topline data for Phase III Crohn's disease study.|
|Next Article:||BioCryst Pharmaceuticals prices public offering at USD8.50 per share.|